Ritlecitinib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Alopecia Areata
Conditions
Severe Alopecia Areata
Trial Timeline
Feb 3, 2025 → May 30, 2025
NCT ID
NCT07200128About Ritlecitinib
Ritlecitinib is a pre-clinical stage product being developed by Pfizer for Severe Alopecia Areata. The current trial status is completed. This product is registered under clinical trial identifier NCT07200128. Target conditions include Severe Alopecia Areata.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05522556 | Pre-clinical | Active |
| NCT07226531 | Pre-clinical | Recruiting |
| NCT07200128 | Pre-clinical | Completed |
| NCT06373458 | Phase 2 | Recruiting |
| NCT06531109 | Pre-clinical | Recruiting |
| NCT06369454 | Phase 1 | Completed |
| NCT06172348 | Phase 1 | Completed |
| NCT05879458 | Phase 2 | Terminated |
| NCT05852340 | Phase 1 | Completed |
Competing Products
20 competing products in Severe Alopecia Areata